Oral liquid for easing mucosa edema after radiotherapy of esophageal cancer

Abstract

The invention belongs to the medical technology field, in particular discloses an oral liquid for easing mucosa edema after the radiotherapy of esophageal cancer. The oral liquid is prepared by using gentamicin sulphate, dexamethasone, 2% xylocaine, 654-2 injectam vitamin B1, vitamin B2, cimetidine and physiological saline as raw materials, respectively and proportionally compounding the raw materials according to the different characteristics of the medicaments, mixing, packaging, sealing and sterilizing. The invention has the advantages of easing oesophagus mucosal congestion and edema caused by radiotherapy, lightening swallowing pain, improving the compliance of esophageal cancer patients on radiotherapy, ensuring that the radiotherapy is smoothly finished, improving the survival quality of patients, and the like. The prescription is new, and the drug preparation is prepared from low-price raw materials with wide resources and is convenient to prepare at low drug cost. Tested by patients in esophageal cancer radiotherapy in 150 clinical cases, the total effective rate reaches 98 percent without any special toxic or side effect.

Description

technical field [0001] The invention belongs to medicines, in particular to an oral solution for improving congestion and edema of esophageal mucosa after radiotherapy for esophageal cancer. Background technique [0002] Esophageal cancer accounts for 2% of malignancies. Early lesions can be treated with surgery, and those with advanced lesions in the middle and upper segments or those with surgical contraindications are more likely to receive radiotherapy. However, radiotherapy can cause radiation esophagitis, causing congestion and edema of the esophageal mucosa, aggravating dysphagia, and reducing the quality of life of patients. Therefore, certain preventive measures during radiotherapy can avoid or reduce acute esophageal injury. At present, drugs such as intravenous omeprazole are mostly used, and the curative effect is slow, the side effects are large, and the treatment cost is also increased. Contents of the invention [0003] The object of the present invention...

AI Technical Summary

Problems solved by technology

At present, omeprazole and other drugs are mostly used intravenously, which has slow curative effect and large side effects, and also increases the cost of treatment.